152 related articles for article (PubMed ID: 17324336)
1. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy.
Hatjiharissi E; Hansen M; Santos DD; Xu L; Leleu X; Dimmock EW; Ho AW; Hunter ZR; Branagan AR; Patterson CJ; Kortsaris A; Verselis S; Fox E; Treon SP
Clin Lymphoma Myeloma; 2007 Jan; 7(4):286-90. PubMed ID: 17324336
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
Treon SP; Hansen M; Branagan AR; Verselis S; Emmanouilides C; Kimby E; Frankel SR; Touroutoglou N; Turnbull B; Anderson KC; Maloney DG; Fox EA
J Clin Oncol; 2005 Jan; 23(3):474-81. PubMed ID: 15659493
[TBL] [Abstract][Full Text] [Related]
3. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
Paiva M; Marques H; Martins A; Ferreira P; Catarino R; Medeiros R
Cancer Genet Cytogenet; 2008 May; 183(1):35-40. PubMed ID: 18474295
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCgammaRIIIa and FCgammaRIIa polymorphisms.
Galimberti S; Palumbo GA; Caracciolo F; Benedetti E; Pelosini M; Brizzi S; Ciabatti E; Fazzi R; Stelitano C; Quintana G; Conte E; Tibullo D; Di Raimondo F; Petrini M
J Chemother; 2007 Jun; 19(3):315-21. PubMed ID: 17594928
[TBL] [Abstract][Full Text] [Related]
5. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.
Farag SS; Flinn IW; Modali R; Lehman TA; Young D; Byrd JC
Blood; 2004 Feb; 103(4):1472-4. PubMed ID: 14563637
[TBL] [Abstract][Full Text] [Related]
6. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
Mitroviç Z; Aurer I; Radman I; Ajdukoviç R; Sertiç J; Labar B
Haematologica; 2007 Jul; 92(7):998-9. PubMed ID: 17606457
[TBL] [Abstract][Full Text] [Related]
7. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
Carlotti E; Palumbo GA; Oldani E; Tibullo D; Salmoiraghi S; Rossi A; Golay J; Pulsoni A; Foà R; Rambaldi A
Haematologica; 2007 Aug; 92(8):1127-30. PubMed ID: 17650444
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.
Weng WK; Negrin RS; Lavori P; Horning SJ
J Clin Oncol; 2010 Jan; 28(2):279-84. PubMed ID: 19933905
[TBL] [Abstract][Full Text] [Related]
9. [Polymorphisms of FcγRIIA, FcγRIIIA and FcγRIIB in patients with immune thrombocytopenia and their clinical significance].
Zhu Y; Zhuang Y; Yang GH; Qiang XF; Yang L; Shen YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):135-9. PubMed ID: 23484707
[TBL] [Abstract][Full Text] [Related]
10. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.
Cartron G; Dacheux L; Salles G; Solal-Celigny P; Bardos P; Colombat P; Watier H
Blood; 2002 Feb; 99(3):754-8. PubMed ID: 11806974
[TBL] [Abstract][Full Text] [Related]
12. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies.
Lejeune J; Thibault G; Ternant D; Cartron G; Watier H; Ohresser M
J Clin Oncol; 2008 Nov; 26(33):5489-91; author reply 5491-2. PubMed ID: 18955438
[No Abstract] [Full Text] [Related]
13. Polymorphisms of Fc gamma-receptors RIIa, RIIIa, and RIIIb in patients with adult periodontal diseases.
Meisel P; Carlsson LE; Sawaf H; Fanghaenel J; Greinacher A; Kocher T
Genes Immun; 2001 Aug; 2(5):258-62. PubMed ID: 11528518
[TBL] [Abstract][Full Text] [Related]
14. FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy.
Tanaka Y; Suzuki Y; Tsuge T; Kanamaru Y; Horikoshi S; Monteiro RC; Tomino Y
Nephrol Dial Transplant; 2005 Nov; 20(11):2439-45. PubMed ID: 16221721
[TBL] [Abstract][Full Text] [Related]
15. Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.
Calemma R; Ottaiano A; Trotta AM; Nasti G; Romano C; Napolitano M; Galati D; Borrelli P; Zanotta S; Cassata A; Castello G; Iaffaioli VR; Scala S
J Transl Med; 2012 Nov; 10():232. PubMed ID: 23171437
[TBL] [Abstract][Full Text] [Related]
16. FcgammaRIIa/IIIa polymorphism and its association with clinical manifestations in Korean lupus patients.
Yun HR; Koh HK; Kim SS; Chung WT; Kim DW; Hong KP; Song GG; Chang HK; Choe JY; Bae SC; Salmon JE; Yoo DH; Kim TY; Kim SY
Lupus; 2001; 10(7):466-72. PubMed ID: 11480843
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
Weng WK; Czerwinski D; Timmerman J; Hsu FJ; Levy R
J Clin Oncol; 2004 Dec; 22(23):4717-24. PubMed ID: 15483014
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism.
Niwa R; Hatanaka S; Shoji-Hosaka E; Sakurada M; Kobayashi Y; Uehara A; Yokoi H; Nakamura K; Shitara K
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6248-55. PubMed ID: 15448014
[TBL] [Abstract][Full Text] [Related]
19. Importance of the Side Chain at Position 296 of Antibody Fc in Interactions with FcγRIIIa and Other Fcγ Receptors.
Isoda Y; Yagi H; Satoh T; Shibata-Koyama M; Masuda K; Satoh M; Kato K; Iida S
PLoS One; 2015; 10(10):e0140120. PubMed ID: 26444434
[TBL] [Abstract][Full Text] [Related]
20. The impact of Fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura.
Ellithy HN; Ahmed SH; Shahin GH; Matter MM; Talatt M
Hematology; 2018 Apr; 23(3):169-174. PubMed ID: 28856973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
